Laura Foster, MD
Hospice and Palliative Medicine · Aurora, CONPI 1952667818
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement.
Across 2 payments — averaging $97.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$100
- Sarepta Therapeutics, Inc.$95
Across 17 payments — averaging $21,641 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$246K
- Amylyx Pharmaceuticals, Inc.$51K
- Biohaven Pharmaceutical Holding Company Ltd.$37K
- UCB SA$22K
- Tanabe Pharma America, Inc.$12K
What the payments were for
- Food & beverage$195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $100 |
| Sarepta Therapeutics, Inc. | 1 | $95 |
How this compares
$195 in reported general payments places this provider in the 70th percentile of 37 hospice and palliative medicine providers in Colorado.
See all hospice and palliative medicine providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 38 | $390,844 |
| Radicava OrsEdaravone | 20 | $276,112 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 15 | $191,141 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $127,260 |
| NuedextaDextromethorphan Hbr/Quinidine | 26 | $41,335 |
| Riluzole | 59 | $3,807 |
| Baclofen | 37 | $730 |
| Atropine Sulfate | 12 | $685 |
| Prednisone | 42 | $236 |
| Nortriptyline Hcl | 12 | $152 |
| Diazepam | 20 | $149 |
| Sodium Chloride0.9 % Sodium Chloride | 12 | $133 |
| Fluoxetine Hcl | 12 | $36 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in Aurora
- Antonia PussoAurora$20K
- Simon Schrick-SenasacAurora$449
- Jonathan TreemAurora$338
- Rebecca ResnikAurora$194
- Samiran BhattacharyaAurora$153
- Kayley SwopeAurora$135
- Benjamin MorescoAurora$80
- Mary Gay Josephine MarangolaAurora$29
- Nora ReznickovaAurora$27
- Katherine MorrisonAurora$19
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.